These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 8785983)
21. [Immunity in guinea pigs following administration of tetanus toxin, antitoxin and anatoxin]. Tuczapska B Pol Tyg Lek; 1972 Dec; 27(51):2023-5. PubMed ID: 4653716 [No Abstract] [Full Text] [Related]
22. Serological potency testing of vaccines against progressive atrophic rhinitis. Oppling V; Kusch M; Rübmann P; Cussler K Dev Biol Stand; 1996; 86():339. PubMed ID: 8785979 [No Abstract] [Full Text] [Related]
23. An antibody induction method in mice for the potency assays of diphtheria and tetanus components in combined vaccines. Maheshwari SC; Sharma SB; Kumar A; Sokhey J J Commun Dis; 1998 Sep; 30(3):139-46. PubMed ID: 10093418 [TBL] [Abstract][Full Text] [Related]
24. Validation of the combined toxin-binding inhibition test for determination of neutralizing antibodies against tetanus and diphtheria toxins in a vaccine field study in Viet Nam. Hong HA; Ke NT; Nhon TN; Thinh ND; van der Gun JW; Hendriks JT; Kreeftenberg JG Bull World Health Organ; 1996; 74(3):275-82. PubMed ID: 8789926 [TBL] [Abstract][Full Text] [Related]
25. Development of an in vitro potency test for tetanus vaccines: an immunoassay based on Hc fragment determination. Prieur S; Broc S; Gal M; Poirier B; Fuchs F Dev Biol (Basel); 2002; 111():37-46. PubMed ID: 12678223 [TBL] [Abstract][Full Text] [Related]
26. [Determination of bulk proteins in tetanus toxoid using the passive cutaneous anaphylaxis test]. Künzel W; Meissner C; Gienapp E Arch Exp Veterinarmed; 1981; 35(5):757-61. PubMed ID: 7337533 [No Abstract] [Full Text] [Related]
27. Potency testing of diphtheria and tetanus toxoids. A reliable, pragmatic and economic approach. Stainer DW Dev Biol Stand; 1996; 86():303-8. PubMed ID: 8785960 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of a guinea pig model to assess interference in the immunogenicity of different components of a combination vaccine comprising diphtheria, tetanus and acellular pertussis (DTaP) vaccine and haemophilus influenzae type b capsular polysaccharide conjugate vaccine. Gupta RK; Anderson R; Cecchini D; Rost B; Xu J; Gendreau K; Saroff DL; Marchant C; Siber GR Biologicals; 1999 Jun; 27(2):167-76. PubMed ID: 10600208 [TBL] [Abstract][Full Text] [Related]
29. Serological assays as alternatives to the Ph Eur challenge test for batch release of tetanus vaccines for human use. Winsnes R; Hendriksen C; Sesardic D; Akkermans A; Daas A Dev Biol Stand; 1999; 101():277-88. PubMed ID: 10566802 [TBL] [Abstract][Full Text] [Related]
30. [Passive hemagglutination reaction as a screening test in assessing antitetanus immunity]. Mihăilescu R; Stoian C; Bălută MM; Durbacă S; Mateescu M; Bittner J; Brestoiu S; Andronescu F; Niţulescu C; Pop C Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol; 1984; 29(3):231-8. PubMed ID: 6505513 [No Abstract] [Full Text] [Related]
31. Sarcoidal reactions in animals intensively immunized with tetanus vaccine. Zóltowska A Arch Immunol Ther Exp (Warsz); 1974; 22(3):341-7. PubMed ID: 4209535 [No Abstract] [Full Text] [Related]
32. Analysis of the immune response to papain digestion products of tetanus toxin. Helting TB; Nau HH Acta Pathol Microbiol Immunol Scand C; 1984 Feb; 92(1):59-63. PubMed ID: 6711309 [TBL] [Abstract][Full Text] [Related]
33. Liposomes as immunological adjuvants for tetanus vaccine. Popescu C; Durbaca S; Ivanov D Roum Arch Microbiol Immunol; 1998; 57(3-4):263-9. PubMed ID: 11845438 [TBL] [Abstract][Full Text] [Related]
35. Use of ELISA to quantify the antitoxin content of commercial equine tetanus antitoxin. Kolbe DR Dev Biol Stand; 1996; 86():336. PubMed ID: 8785976 [No Abstract] [Full Text] [Related]
36. Reduction in animal usage for potency testing of diphtheria and tetanus toxoids. Stainer DW; Jakus CM; Sparkes JD Dev Biol Stand; 1986; 65():241-4. PubMed ID: 3556773 [No Abstract] [Full Text] [Related]
37. Opportunities to reduce the use of animals in the potency and toxicity testing of toxoid vaccines. Knight PA Dev Biol Stand; 1996; 86():185-97. PubMed ID: 8785948 [TBL] [Abstract][Full Text] [Related]
38. Reduction of the ganglioside binding activity of the tetanus toxin HC fragment destroys immunogenicity: implications for development of novel tetanus vaccines. Qazi O; Sesardic D; Tierney R; Söderbäck Z; Crane D; Bolgiano B; Fairweather N Infect Immun; 2006 Aug; 74(8):4884-91. PubMed ID: 16861677 [TBL] [Abstract][Full Text] [Related]
39. Serological methods for potency testing of tetanus toxoid vaccines for human use. Hendriksen C; Winsnes R Dev Biol (Basel); 2002; 111():131-40. PubMed ID: 12678232 [TBL] [Abstract][Full Text] [Related]
40. The use of alternatives to animal tests in developing countries. Hong HA; Hendriks J Dev Biol Stand; 1999; 101():209-14. PubMed ID: 10566795 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]